NASDAQ: PTGX

Protagonist Therapeutics (PTGX) Stock Analysis & Forecast

Nov 13 close

$130.95−3.43 (−2.6%)

Gekko Brief

AI summaryNov 9 close

Protagonist Therapeutics moved this week on Q3 2026 results and an FDA approval. The company reported EPS of $3.07 on revenue of $274.41 million, swinging to a $220.0 million net income from a $39.3 million loss a year earlier, with earnings and revenue surpassing estimates. The FDA approved MIMRYLO (rusfertide) for erythrocytosis in adults with polycythemia vera, triggering $275 million in payments to the company. Wall Street Zen upgraded the stock to "Strong-Buy," aligning with a broader "Buy" consensus and an average price target cited at $166.67.

PTGX closed at $135.90, up 2.9%, sitting between its 50-day average of $141.35 and 200-day average of $118.24. The stock has gained 31.3% over six months and 70.3% over the past year, though it is down 5.4% over one month and 8.4% over three months. The GekkoIndex reads 62, placing the stock in the Accumulation zone. Price sits 13.1% below the Gekko Fair Value of $156.34.

Over the next 20 trading days, the next earnings date falls on 24 February 2027, 101 days away, outside a typical holding window. Insider, Congress and unusual options activity show no data in their respective windows, though one billionaire holder is noted. Thirteen analyst firms carry buy ratings, with a consensus target of $178.57 and consensus upside of 31.4%. Seasonality from this point has averaged a 5% gain over 20 trading days across 5 years, rising in 2 of them, with typical 20-day moves near 10.1%.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Protagonist Therapeutics price vs fair value

$157.12$130.95Nov ’25May ’26Nov ’26
Close $130.95200-day averageGekko Fair Value $157.12

Protagonist Therapeutics quick facts

Market cap
$8.55B
P/E ratio
28.1
Forward P/E
36.9
EPS, TTM
$4.73
Revenue, TTM
$551.7M
Profit margin
62%
Dividend yield
—
Beta
1.22
Volume
759,913 avg 599,304
1-year return
+54.3%
Typical daily move
±4.5%
Typical 20-day move
±10.1%
50-day average
$140.30
200-day average
$119.29
Next earnings
Feb 24 after close
Shares outstanding
65.27M
52-week range
$77.00$160.81

Protagonist Therapeutics swing-trade checklist

Protagonist Therapeutics scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

4 supportive1 mixed0 headwinds

  • Trendmixed

    Averages disagree

    Close $130.95 sits between the 50-day ($140.30) and 200-day ($119.29) averages, or the averages disagree.

    See the chart
  • GekkoIndexsupportive

    63.2, Accumulation

    Reading 63.2 is in the Accumulation zone.

    See the GekkoIndex
  • Fair valuesupportive

    16.7% below

    Price is 16.7% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 101 days

    Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +4.0% on average

    From this point in the calendar, the next 20 trading days averaged +4% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Protagonist Therapeutics stock chart and price history

Protagonist Therapeutics closed at $130.95 on Nov 13, 2026, +54.3% over the past year, inside a 52-week range of $77.00 to $160.81.

Close50-day average200-day averageVolume
Protagonist Therapeutics share price, past year, with 50-day and 200-day moving averages and volume$60$80$100$120$140$160DecJan 2026FebMarAprMayJunJulAugSepOctNov130.95

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−4.1%
3 months
−17.4%
6 months
+28.2%
1 year
+54.3%
The full PTGX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PTGX in Gekko

Follow Protagonist Therapeutics through every session

Put PTGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track PTGX in GekkoFree for 7 days. No credit card required.

About Protagonist Therapeutics

Protagonist Therapeutics develops therapies built around peptide molecules, with work concentrated on blood disorders and on conditions driven by inflammation or immune activity. It is best recognized for rusfertide, also called PTG-300, an injectable compound that mimics hepcidin and is being tested in Phase II studies for polycythemia vera, hereditary hemochromatosis, and related blood conditions. Alongside this, the company is developing PN-943, an oral peptide designed to block alpha-4-beta-7 integrin for inflammatory bowel disease, and PN-235, an oral compound aimed at the interleukin-23 receptor for both IBD and other conditions outside that category.

The company advances its pipeline in part through a licensing and collaborative arrangement with Janssen Biotech, Inc., pairing its own drug discovery work with an outside partner as programs move through development.

Protagonist Therapeutics was founded in 2006 and is headquartered in Newark, California. Its shares trade on the NASDAQ under the ticker PTGX.

Listed
NASDAQ
Sector
Health technology
Industry
Pharmaceuticals: major
Website
protagonist-inc.com

Protagonist Therapeutics GekkoIndex: the smart money zone

Protagonist Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.2, in the Accumulation zone, down 0.8 points over five sessions.

010063.2Accumulation

Down 0.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying7Too few readings yet
Accumulation (current zone)159+1.8%+4.1%+5.7%+24.0%
Neutral492+1.5%+2.9%+6.3%+12.9%
Distribution40−0.9%−1.1%+0.6%+7.6%
Selling4Too few readings yet

Average PTGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the PTGX price, zone by zone.Track PTGX in Gekko

Is Protagonist Therapeutics stock overvalued? Gekko Fair Value

Protagonist Therapeutics trades 16.7% below Gekko Fair Value of $157.12, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Protagonist Therapeutics shares are worth, recalculated every trading day.

$157.12

Gekko Fair Value, Nov 14, 2026

16.7% Undervalued

At the end of Aug 2026 the price was 7.3% below the estimate.

Gekko Fair ValueShare price, month end
$157$131Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open PTGX in Gekko

Protagonist Therapeutics insider and Congress trading

No open-market insider purchases were filed for Protagonist Therapeutics, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for PTGX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every PTGX insider filing, plotted on the chart in Gekko.Open PTGX in Gekko

Congress trades last 90 days

No trades in PTGX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for PTGX, plotted on the chart in Gekko.Open PTGX in Gekko

Buybacks

Protagonist Therapeutics has been buying back its own shares.

Bought back, quarter ended Sep 30, 2026
$5.79M
As a share of market cap
0.07%

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds PTGX.

1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Protagonist Therapeutics earnings: next date and track record

Protagonist Therapeutics reports on Feb 24, 2027, after the close (101 days away), and beat the EPS estimate in 5 of its last 8 reports.

5 of 8reports beat the EPS estimate
±4.1%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

−2.9%Nov ’24−6.5%Feb ’25−2.7%May ’25−5.5%Aug ’25+2.1%Nov ’25+1.1%Feb ’26+4.5%May ’26+7.6%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$2.29
est $2.23
+2.7%$213.5M
est $198.7M
+7.5%+7.6%
May 5, 2026$0.05
est −$0.65
+107.7%$56.37M
est $11.70M
+381.7%+4.5%
Feb 25, 2026−$0.69
est −$0.53
−30.2%$7.44M
est $8.74M
−14.9%+1.1%
Nov 6, 2025−$0.62
est −$0.59
−5.1%$4.71M
est $14.92M
−68.4%+2.1%
Aug 6, 2025−$0.55
est −$0.53
−3.8%$5.55M
est $8.43M
−34.2%−5.5%
May 6, 2025−$0.19
est −$0.50
+62.0%$28.32M
est $6.56M
+332.0%−2.7%
Feb 21, 2025$1.98
est $0.06
+3,200.0%$170.6M
est $81.01M
+110.6%−6.5%
Nov 7, 2024−$0.54
est −$0.59
+8.5%$4.68M
est $38.81M
−88.0%−2.9%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Protagonist Therapeutics stock forecast and analyst price targets

Analysts’ average 12-month price target for Protagonist Therapeutics is $182.36, +39.3% from the last close, from 13 firms rating the stock in the last 90 days.

$182.36consensus 12-month target, +39.3% from the last close
Low $151High $221
Buy13
Hold0
Sell0

Each firm’s latest rating in the last 90 days: 13 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10UBSBuy, maintained$184+40.5%
Nov 9WedbushBuy, maintained$173+32.1%
Nov 9BMO CapitalBuy, maintained$190+45.1%
Nov 9J.P. MorganBuy, reiterated$151+15.3%
Nov 6H.C. WainwrightBuy, reiterated$221+68.8%
+5.7%average 20-day move after past Accumulation readings
+4.0%average move over the next 20 trading days in the last 5 years
±4.5%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Protagonist Therapeutics seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Protagonist Therapeutics averaged +4.0% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−16.8%2021+6.6%2022+23.6%2023+0.1%2024+12.0%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.2%2 of 5
Next 10 trading days−0.3%3 of 5
Next 15 trading days+3.7%2 of 5
Next 20 trading days+4.0%3 of 5
Next 30 trading days+11.1%3 of 5

For scale, PTGX’s typical 20-trading-day move in either direction is about 10.1%.

Protagonist Therapeutics market cap and key statistics

Protagonist Therapeutics’s market cap is $8.55B, with a P/E ratio of 28.1 and revenue of $551.7M over the last twelve months.

Valuation

Market cap
$8.55B
P/E ratio
28.1
Forward P/E
36.9
EPS, TTM
$4.73
Gekko Fair Value
$157.12

Trading

Volume
759,913
Avg volume, 20 days
599,304
52-week high
$160.81
52-week low
$77.00
Shares outstanding
65.27M

Financials

Revenue, TTM
$551.7M
Profit margin
62%
Return on equity
39.6%
Quarterly earnings growth, YoY
+351.3%

Risk and income

Beta
1.22
Typical daily move
±4.5%
Typical 20-day move
±10.1%

Protagonist Therapeutics stock news this week

Coverage of Protagonist Therapeutics this week reads positive: 3 positive, 0 neutral and 0 negative headlines.

News sentiment positive

Protagonist Therapeutics peers

Protagonist Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
LLYEli Lilly+1.0%Neutral24.0% above
JNJJohnson & Johnson+0.3%Neutral4.4% above
ABBVAbbVie−0.5%Neutral23.7% above
MRKMerck+0.3%Neutral8.2% below
AZNAstraZeneca−0.2%Neutral34.6% below
PFEPfizer−0.1%Accumulation8.9% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Pharmaceuticals: major

Protagonist Therapeutics stock FAQ

What is Protagonist Therapeutics’s market cap?

Protagonist Therapeutics’s market cap is $8.55B at the Nov 13, 2026 close of $130.95, with 65.27M shares outstanding. The shares trade on a P/E ratio of 28.1.

What is the Protagonist Therapeutics stock forecast?

The consensus analyst 12-month price target for Protagonist Therapeutics is $182.36, +39.3% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Protagonist Therapeutics stock overvalued or undervalued?

On Gekko’s estimate Protagonist Therapeutics is undervalued: the Nov 13, 2026 close of $130.95 is 16.7% below Gekko Fair Value of $157.12. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Protagonist Therapeutics report earnings next?

Protagonist Therapeutics is expected to report on Feb 24, 2027, after the market closes (101 days away). Analysts expect earnings of −$0.15 per share on revenue of $45.42M. Protagonist Therapeutics beat the earnings estimate in 5 of its last 8 reports, moving 4.1% on average across the report.

What is Protagonist Therapeutics’s 52-week high and low?

Protagonist Therapeutics’s 52-week high is $160.81 and its 52-week low is $77.00; it closed at $130.95 on Nov 13, 2026, +54.3% over the past year.

Is Protagonist Therapeutics stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Protagonist Therapeutics the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.